Healthcare • Biotechnology
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer.
Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Company profile from EODHD, stored Nov 6, 2026.
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 28, 2026 | — | — | — | -$6.5M | -$3.2M |
| Mar 2026filed Mar 31, 2026 | — | — | — | -$6.5M | -$5.3M |
| Dec 2025filed Feb 9, 2026 | — | — | — | -$6.8M | -$5.7M |
| Sep 2025filed Nov 25, 2025 | — | — | — | -$10.8M | -$9.8M |
| Jun 2025filed Aug 12, 2025 | — | — | — | -$14.5M | -$13.2M |
| Mar 2025filed May 13, 2025 | — | — | — | -$12.5M | -$11.2M |
| Dec 2024filed Feb 12, 2025 | — | — | — | -$13.6M | -$12.1M |
| Sep 2024filed Dec 23, 2024 | — | — | — | -$14.3M | -$11.6M |
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2025filed Nov 25, 2025 | — | — | — | -$51.4M | -$46.4M |
| Sep 2024filed Dec 23, 2024 | — | — | — | -$52.9M | -$43.0M |
| Sep 2023filed Nov 27, 2023 | — | — | — | -$47.5M | -$47.5M |
| Sep 2022filed Nov 28, 2022 | — | — | — | -$51.0M | -$48.0M |
| Sep 2021filed Nov 24, 2021 | — | — | — | -$42.0M | -$37.9M |
| Sep 2020filed Dec 28, 2020 | — | — | — | -$31.1M | -$26.3M |
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched AVXL. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
12,548,190 shares short
-1,018,334 shares (-7.5%) vs Sep 30, 2026
14% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
13,566,524 shares short
-766,854 shares (-5.4%) vs Sep 15, 2026
15.1% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
14,333,378 shares short
+435,238 shares (+3.1%) vs Aug 31, 2026
Share of float unavailable. Published Sep 24, 2026.
Settlement Aug 31, 2026
13,898,140 shares short
-208,350 shares (-1.5%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
14,106,490 shares short
-320,180 shares (-2.2%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
14,426,670 shares short
+286,610 shares (+2%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
See the recorded cash amounts and dates behind AVXL’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
1 for 4 · reverse split
Effective Oct 7, 2015
Each 4 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workSign in to see your position size
We’ll show you if AVXL is in your portfolio and how much it contributes.
Sign inLoading market dates
19 smart-money holders: institutions with a high Holder IQ
Sentiment: unknown
No recent insider trades detected.
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 6
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
177 filers reported a long position in AVXL for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
65.7%
of the 37M shares 13-F filers reported
Moves vs Q1 2026
7 added3 trimmed
Net shares held
-3.8%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | $20.9M · 8.1M shares | 8.1M | +5.9% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | $10.5M · 4.1M shares | 4.1M | +4.9% |
| 3 | TWO SIGMA INVESTMENTS, LP | $7.9M · 3M shares | 3M | -6.2% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | $6.2M · 2.4M shares | 2.4M | +10% |
| 5 | STATE STREET CORP | $5M · 1.9M shares | 1.9M | -57.4% |
| 6 | FEDERATED HERMES, INC. | $2.8M · 1.1M shares | 1.1M | +101.4% |
| 7 | AQR CAPITAL MANAGEMENT LLC | $2.5M · 963K shares | 963K | +27.2% |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | $2.5M · 948.6K shares | 948.6K | +21.1% |
| 9 | Summit Financial, LLC | $2.4M · 909.4K shares | 909.4K | -3.3% |
| 10 | GOLDMAN SACHS GROUP INC | $2.3M · 890.6K shares | 890.6K | +10.7% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inHolders of more than 5% of AVXL file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Jul 31, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive | 5.03% |
| Mar 26, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.